http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 26 Oct 2026 04:34:54 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR305+at+Deutsche+Bank/27229725.html Deutsche Bank analyst Emmanuel Papadakis raised the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR305.00 (from EUR295.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR305+at+Deutsche+Bank/27229725.html Mon, 26 Oct 2026 04:34:54 -0400 UCBJY http://www.streetinsider.com/Analyst+PT+Change/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR305+at+Deutsche+Bank/27229725.html Deutsche Bank analyst Emmanuel Papadakis raised the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR305.00 (from EUR295.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR305+at+Deutsche+Bank/27229725.html Mon, 26 Oct 2026 04:34:54 -0400 UCBJY http://www.streetinsider.com/Intl+Ratings/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR305+at+Deutsche+Bank/27229725.html Deutsche Bank analyst Emmanuel Papadakis raised the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR305.00 (from EUR295.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR305+at+Deutsche+Bank/27229725.html Mon, 26 Oct 2026 04:34:54 -0400 UCBJY http://www.streetinsider.com/Analyst+PT+Change/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR305+at+Deutsche+Bank/27229725.html Deutsche Bank analyst Emmanuel Papadakis raised the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR305.00 (from EUR295.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR305+at+Deutsche+Bank/27229725.html Mon, 26 Oct 2026 04:34:54 -0400 UCBJY http://www.streetinsider.com/Press+Releases/UCB+Establishes+the+Emmanuel+Janssen+Endowed+Chair+for+the+Evaluation+of+Medicines+at+Brigham+and+Women%27s+Hospital/27227568.html <div class="xn-content"> <ul type="disc"> <li>Permanent endowment advances pharmacoepidemiology and real-world evidence research</li> <li><person>Sebastian Schneeweiss</person>, MD, ScD, an internationally recognized pharmacoepidemiologist whose research focuses on improving medication safety, effectiveness, and value through real-world evidence, has been named the chair's inaugural incumbent.</li> http://www.streetinsider.com/Press+Releases/UCB+Establishes+the+Emmanuel+Janssen+Endowed+Chair+for+the+Evaluation+of+Medicines+at+Brigham+and+Women%27s+Hospital/27227568.html Fri, 23 Oct 2026 15:02:00 -0400 UCBJY http://www.streetinsider.com/PRNewswire/UCB+Establishes+the+Emmanuel+Janssen+Endowed+Chair+for+the+Evaluation+of+Medicines+at+Brigham+and+Women%27s+Hospital/27227568.html <div class="xn-content"> <ul type="disc"> <li>Permanent endowment advances pharmacoepidemiology and real-world evidence research</li> <li><person>Sebastian Schneeweiss</person>, MD, ScD, an internationally recognized pharmacoepidemiologist whose research focuses on improving medication safety, effectiveness, and value through real-world evidence, has been named the chair's inaugural incumbent.</li> http://www.streetinsider.com/PRNewswire/UCB+Establishes+the+Emmanuel+Janssen+Endowed+Chair+for+the+Evaluation+of+Medicines+at+Brigham+and+Women%27s+Hospital/27227568.html Fri, 23 Oct 2026 15:02:00 -0400 UCBJY http://www.streetinsider.com/Analyst+PT+Change/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html (Updated - October 23, 2026 9:33 AM EDT) <p>TD Cowen analyst Stacy Ku raised the price target on UCB SA (UCB:BB) (OTC: UCBJY) to EUR340.00 (from EUR305.00) while maintaining a Buy rating.</p><p>The analyst commented: "Still At 15x '28E With €200MM Bimzelx Beat/Luti Data; We view ABBV's luti PhIII as a reminder for HS' difficult development path that protects Bimzelx BIC efficacy moat. While we want NVS' remi to be approved/expand the market, KOL views do not suggest the Q4 PhIII is a sure success. UCB's new 2026 guide also suggests a strong Bimzelx cons beat of €200MM. Our DCF-based PT is http://www.streetinsider.com/Analyst+PT+Change/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html Fri, 23 Oct 2026 09:33:44 -0400 UCBJY http://www.streetinsider.com/Intl+Ratings/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html (Updated - October 23, 2026 9:33 AM EDT) <p>TD Cowen analyst Stacy Ku raised the price target on UCB SA (UCB:BB) (OTC: UCBJY) to EUR340.00 (from EUR305.00) while maintaining a Buy rating.</p><p>The analyst commented: "Still At 15x '28E With €200MM Bimzelx Beat/Luti Data; We view ABBV's luti PhIII as a reminder for HS' difficult development path that protects Bimzelx BIC efficacy moat. While we want NVS' remi to be approved/expand the market, KOL views do not suggest the Q4 PhIII is a sure success. UCB's new 2026 guide also suggests a strong Bimzelx cons beat of €200MM. Our DCF-based PT is http://www.streetinsider.com/Intl+Ratings/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html Fri, 23 Oct 2026 09:33:44 -0400 UCBJY http://www.streetinsider.com/Analyst+Comments/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html (Updated - October 23, 2026 9:33 AM EDT) <p>TD Cowen analyst Stacy Ku raised the price target on UCB SA (UCB:BB) (OTC: UCBJY) to EUR340.00 (from EUR305.00) while maintaining a Buy rating.</p><p>The analyst commented: "Still At 15x '28E With €200MM Bimzelx Beat/Luti Data; We view ABBV's luti PhIII as a reminder for HS' difficult development path that protects Bimzelx BIC efficacy moat. While we want NVS' remi to be approved/expand the market, KOL views do not suggest the Q4 PhIII is a sure success. UCB's new 2026 guide also suggests a strong Bimzelx cons beat of €200MM. Our DCF-based PT is http://www.streetinsider.com/Analyst+Comments/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html Fri, 23 Oct 2026 09:33:44 -0400 UCBJY http://www.streetinsider.com/Analyst+PT+Change/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html (Updated - October 23, 2026 9:33 AM EDT) <p>TD Cowen analyst Stacy Ku raised the price target on UCB SA (UCB:BB) (OTC: UCBJY) to EUR340.00 (from EUR305.00) while maintaining a Buy rating.</p><p>The analyst commented: "Still At 15x '28E With €200MM Bimzelx Beat/Luti Data; We view ABBV's luti PhIII as a reminder for HS' difficult development path that protects Bimzelx BIC efficacy moat. While we want NVS' remi to be approved/expand the market, KOL views do not suggest the Q4 PhIII is a sure success. UCB's new 2026 guide also suggests a strong Bimzelx cons beat of €200MM. Our DCF-based PT is http://www.streetinsider.com/Analyst+PT+Change/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html Fri, 23 Oct 2026 09:33:44 -0400 UCBJY http://www.streetinsider.com/Intl+Ratings/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html (Updated - October 23, 2026 9:33 AM EDT) <p>TD Cowen analyst Stacy Ku raised the price target on UCB SA (UCB:BB) (OTC: UCBJY) to EUR340.00 (from EUR305.00) while maintaining a Buy rating.</p><p>The analyst commented: "Still At 15x '28E With €200MM Bimzelx Beat/Luti Data; We view ABBV's luti PhIII as a reminder for HS' difficult development path that protects Bimzelx BIC efficacy moat. While we want NVS' remi to be approved/expand the market, KOL views do not suggest the Q4 PhIII is a sure success. UCB's new 2026 guide also suggests a strong Bimzelx cons beat of €200MM. Our DCF-based PT is http://www.streetinsider.com/Intl+Ratings/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html Fri, 23 Oct 2026 09:33:44 -0400 UCBJY http://www.streetinsider.com/Analyst+Comments/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html (Updated - October 23, 2026 9:33 AM EDT) <p>TD Cowen analyst Stacy Ku raised the price target on UCB SA (UCB:BB) (OTC: UCBJY) to EUR340.00 (from EUR305.00) while maintaining a Buy rating.</p><p>The analyst commented: "Still At 15x '28E With €200MM Bimzelx Beat/Luti Data; We view ABBV's luti PhIII as a reminder for HS' difficult development path that protects Bimzelx BIC efficacy moat. While we want NVS' remi to be approved/expand the market, KOL views do not suggest the Q4 PhIII is a sure success. UCB's new 2026 guide also suggests a strong Bimzelx cons beat of €200MM. Our DCF-based PT is http://www.streetinsider.com/Analyst+Comments/UCB+SA+%28UCB%3ABB%29+%28UCBJY%29+PT+Raised+to+EUR340+at+TD+Cowen/27225536.html Fri, 23 Oct 2026 09:33:44 -0400 UCBJY http://www.streetinsider.com/FDA/FDA+approves+UCB%27s+Zilbrysq+autoinjector+for+myasthenia+gravis/27195551.html <p>UCB (Euronext Brussels: UCB) announced that the U.S. Food and Drug Administration has approved an autoinjector delivery option for Zilbrysq (zilucoplan), its existing treatment for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.</p> <p>Previously available only as a prefilled syringe, Zilbrysq can now be self-administered via the autoinjector device, which is designed to automatically deliver a pre-defined dose when activated against the skin. The drug remains a once-daily subcutaneous injection.</p> <p>The approval was supported by data from two studies. A Phase 1 crossover study in 14 healthy volunteers established bioequivalence between the autoinjector and the prefilled http://www.streetinsider.com/FDA/FDA+approves+UCB%27s+Zilbrysq+autoinjector+for+myasthenia+gravis/27195551.html Fri, 16 Oct 2026 07:00:27 -0400 UCBJY http://www.streetinsider.com/Press+Releases/UCB+announces+U.S.+FDA+approval+for+ZILBRYSQ%C2%AE+%28zilucoplan%29+autoinjector+self-administration+for+adults+living+with+generalized+myasthenia+gravis/27195530.html <div class="xn-content"> <ul type="disc"> <li>ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous autoinjector for adults living with generalized myasthenia gravis (gMG) in the U.S.¹</li> <li>ZILBRYSQ now offers two self-administration options for adults living with gMG who are anti-acetylcholine receptor (AChR) antibody positive.¹</li> http://www.streetinsider.com/Press+Releases/UCB+announces+U.S.+FDA+approval+for+ZILBRYSQ%C2%AE+%28zilucoplan%29+autoinjector+self-administration+for+adults+living+with+generalized+myasthenia+gravis/27195530.html Fri, 16 Oct 2026 07:00:00 -0400 UCBJY http://www.streetinsider.com/PRNewswire/UCB+announces+U.S.+FDA+approval+for+ZILBRYSQ%C2%AE+%28zilucoplan%29+autoinjector+self-administration+for+adults+living+with+generalized+myasthenia+gravis/27195530.html <div class="xn-content"> <ul type="disc"> <li>ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous autoinjector for adults living with generalized myasthenia gravis (gMG) in the U.S.¹</li> <li>ZILBRYSQ now offers two self-administration options for adults living with gMG who are anti-acetylcholine receptor (AChR) antibody positive.¹</li> http://www.streetinsider.com/PRNewswire/UCB+announces+U.S.+FDA+approval+for+ZILBRYSQ%C2%AE+%28zilucoplan%29+autoinjector+self-administration+for+adults+living+with+generalized+myasthenia+gravis/27195530.html Fri, 16 Oct 2026 07:00:00 -0400 UCBJY http://www.streetinsider.com/Press+Releases/UCB+Launches+Wear+It+Out%2C+a+Community-Driven+Program+Created+For+and+With+People+Living+With+Hidradenitis+Suppurativa%2C+Plaque+Psoriasis%2C+and+Psoriatic+Arthritis/27178397.html <div class="xn-content"> <ul type="disc"> <li>The Wear It Out program was created with and for patient advocates to reduce stigma and increase awareness of the everyday, often unseen compromises and decisions people make because of their conditions.</li> <li>Artist <person>Sophia Yeshi</person> brought real stories of people living with HS, PSO, and PsA to http://www.streetinsider.com/Press+Releases/UCB+Launches+Wear+It+Out%2C+a+Community-Driven+Program+Created+For+and+With+People+Living+With+Hidradenitis+Suppurativa%2C+Plaque+Psoriasis%2C+and+Psoriatic+Arthritis/27178397.html Tue, 13 Oct 2026 09:00:00 -0400 UCBJY http://www.streetinsider.com/PRNewswire/UCB+Launches+Wear+It+Out%2C+a+Community-Driven+Program+Created+For+and+With+People+Living+With+Hidradenitis+Suppurativa%2C+Plaque+Psoriasis%2C+and+Psoriatic+Arthritis/27178397.html <div class="xn-content"> <ul type="disc"> <li>The Wear It Out program was created with and for patient advocates to reduce stigma and increase awareness of the everyday, often unseen compromises and decisions people make because of their conditions.</li> <li>Artist <person>Sophia Yeshi</person> brought real stories of people living with HS, PSO, and PsA to http://www.streetinsider.com/PRNewswire/UCB+Launches+Wear+It+Out%2C+a+Community-Driven+Program+Created+For+and+With+People+Living+With+Hidradenitis+Suppurativa%2C+Plaque+Psoriasis%2C+and+Psoriatic+Arthritis/27178397.html Tue, 13 Oct 2026 09:00:00 -0400 UCBJY http://www.streetinsider.com/Intl+Ratings/TD+Cowen+on+UCB+SA+%28UCB%3ABB%29+%28UCBJY%29%3A+%27Likely+UCB+Upside+With+Q4+HS+Updates+%26+Promising+Pipeline%27/27174669.html <p>TD Cowen analyst Stacy Ku reiterated a Buy rating and EUR305.00 price target on UCB SA (UCB:BB) (OTC: UCBJY).</p><p>The analyst commented: "Likely UCB Upside With Q4 HS Updates & Promising Pipeline; At our 29th Annual Therapeutics Conference, we hosted Dermatology panels that confirm Bimzelx's incumbency in HS, with high likelihood of a relief rally from 15x cons '27E. KOLs are also positive for galvokimig in AD/respiratory expansion, rezanecel in epilepsy and cizutamig for autoimmune interstitial lung disease. With a catalyst rich '27-29, we would add as ~20x cons '28E suggests 60%+ upside."</p> http://www.streetinsider.com/Intl+Ratings/TD+Cowen+on+UCB+SA+%28UCB%3ABB%29+%28UCBJY%29%3A+%27Likely+UCB+Upside+With+Q4+HS+Updates+%26+Promising+Pipeline%27/27174669.html Mon, 12 Oct 2026 09:40:20 -0400 UCBJY http://www.streetinsider.com/Analyst+Comments/TD+Cowen+on+UCB+SA+%28UCB%3ABB%29+%28UCBJY%29%3A+%27Likely+UCB+Upside+With+Q4+HS+Updates+%26+Promising+Pipeline%27/27174669.html <p>TD Cowen analyst Stacy Ku reiterated a Buy rating and EUR305.00 price target on UCB SA (UCB:BB) (OTC: UCBJY).</p><p>The analyst commented: "Likely UCB Upside With Q4 HS Updates & Promising Pipeline; At our 29th Annual Therapeutics Conference, we hosted Dermatology panels that confirm Bimzelx's incumbency in HS, with high likelihood of a relief rally from 15x cons '27E. KOLs are also positive for galvokimig in AD/respiratory expansion, rezanecel in epilepsy and cizutamig for autoimmune interstitial lung disease. With a catalyst rich '27-29, we would add as ~20x cons '28E suggests 60%+ upside."</p> http://www.streetinsider.com/Analyst+Comments/TD+Cowen+on+UCB+SA+%28UCB%3ABB%29+%28UCBJY%29%3A+%27Likely+UCB+Upside+With+Q4+HS+Updates+%26+Promising+Pipeline%27/27174669.html Mon, 12 Oct 2026 09:40:20 -0400 UCBJY http://www.streetinsider.com/Intl+Ratings/TD+Cowen+on+UCB+SA+%28UCB%3ABB%29+%28UCBJY%29%3A+%27Likely+UCB+Upside+With+Q4+HS+Updates+%26+Promising+Pipeline%27/27174669.html <p>TD Cowen analyst Stacy Ku reiterated a Buy rating and EUR305.00 price target on UCB SA (UCB:BB) (OTC: UCBJY).</p><p>The analyst commented: "Likely UCB Upside With Q4 HS Updates & Promising Pipeline; At our 29th Annual Therapeutics Conference, we hosted Dermatology panels that confirm Bimzelx's incumbency in HS, with high likelihood of a relief rally from 15x cons '27E. KOLs are also positive for galvokimig in AD/respiratory expansion, rezanecel in epilepsy and cizutamig for autoimmune interstitial lung disease. With a catalyst rich '27-29, we would add as ~20x cons '28E suggests 60%+ upside."</p> http://www.streetinsider.com/Intl+Ratings/TD+Cowen+on+UCB+SA+%28UCB%3ABB%29+%28UCBJY%29%3A+%27Likely+UCB+Upside+With+Q4+HS+Updates+%26+Promising+Pipeline%27/27174669.html Mon, 12 Oct 2026 09:40:20 -0400 UCBJY http://www.streetinsider.com/Analyst+Comments/TD+Cowen+on+UCB+SA+%28UCB%3ABB%29+%28UCBJY%29%3A+%27Likely+UCB+Upside+With+Q4+HS+Updates+%26+Promising+Pipeline%27/27174669.html <p>TD Cowen analyst Stacy Ku reiterated a Buy rating and EUR305.00 price target on UCB SA (UCB:BB) (OTC: UCBJY).</p><p>The analyst commented: "Likely UCB Upside With Q4 HS Updates & Promising Pipeline; At our 29th Annual Therapeutics Conference, we hosted Dermatology panels that confirm Bimzelx's incumbency in HS, with high likelihood of a relief rally from 15x cons '27E. KOLs are also positive for galvokimig in AD/respiratory expansion, rezanecel in epilepsy and cizutamig for autoimmune interstitial lung disease. With a catalyst rich '27-29, we would add as ~20x cons '28E suggests 60%+ upside."</p> http://www.streetinsider.com/Analyst+Comments/TD+Cowen+on+UCB+SA+%28UCB%3ABB%29+%28UCBJY%29%3A+%27Likely+UCB+Upside+With+Q4+HS+Updates+%26+Promising+Pipeline%27/27174669.html Mon, 12 Oct 2026 09:40:20 -0400 UCBJY http://www.streetinsider.com/Press+Releases/UCB+Dedicates+Site+for+New+U.S.+Biologics+Manufacturing+Campus+in+Georgia/27171421.html <div class="xn-content"> <ul type="disc"> <li><b>Site dedication signals continued momentum for UCB's first <location value="LC/us" idsrc="xmltag.org" >U.S</location>. manufacturing campus</b></li> <li><b>Emphasizes long-term commitment to advancing innovation, patient access, and workforce development in Gwinnett County and surrounding areas</b></li> <li><b>New http://www.streetinsider.com/Press+Releases/UCB+Dedicates+Site+for+New+U.S.+Biologics+Manufacturing+Campus+in+Georgia/27171421.html Fri, 09 Oct 2026 15:58:00 -0400 UCBJY http://www.streetinsider.com/PRNewswire/UCB+Dedicates+Site+for+New+U.S.+Biologics+Manufacturing+Campus+in+Georgia/27171421.html <div class="xn-content"> <ul type="disc"> <li><b>Site dedication signals continued momentum for UCB's first <location value="LC/us" idsrc="xmltag.org" >U.S</location>. manufacturing campus</b></li> <li><b>Emphasizes long-term commitment to advancing innovation, patient access, and workforce development in Gwinnett County and surrounding areas</b></li> <li><b>New http://www.streetinsider.com/PRNewswire/UCB+Dedicates+Site+for+New+U.S.+Biologics+Manufacturing+Campus+in+Georgia/27171421.html Fri, 09 Oct 2026 15:58:00 -0400 UCBJY http://www.streetinsider.com/Press+Releases/UCB+data+presented+at+2026+AANEM+Annual+Meeting+and+MGFA+Scientific+Session+underscore+leadership+in+advancing+targeted+treatments+for+gMG/27117696.html <div class="xn-content"> <ul type="disc"> <li><b>Analyses of achievement of minimal symptom expression in generalized myasthenia gravis (gMG) patients receiving either ZILBRYSQ</b><b>^®</b><b> (zilucoplan) or RYSTIGGO</b><b>^®</b><b> (rozanolixizumab-noli) treatment</b>: 120-week post hoc analysis of Phase 3 RAISE-XT open-label extension for zilucoplan and Phase 3 MycarinG study for rozanolixizumab and its open-label extensions^1,2</li> <li><b>Underrecognized perspectives of http://www.streetinsider.com/Press+Releases/UCB+data+presented+at+2026+AANEM+Annual+Meeting+and+MGFA+Scientific+Session+underscore+leadership+in+advancing+targeted+treatments+for+gMG/27117696.html Tue, 29 Sep 2026 08:00:00 -0400 UCBJY http://www.streetinsider.com/PRNewswire/UCB+data+presented+at+2026+AANEM+Annual+Meeting+and+MGFA+Scientific+Session+underscore+leadership+in+advancing+targeted+treatments+for+gMG/27117696.html <div class="xn-content"> <ul type="disc"> <li><b>Analyses of achievement of minimal symptom expression in generalized myasthenia gravis (gMG) patients receiving either ZILBRYSQ</b><b>^®</b><b> (zilucoplan) or RYSTIGGO</b><b>^®</b><b> (rozanolixizumab-noli) treatment</b>: 120-week post hoc analysis of Phase 3 RAISE-XT open-label extension for zilucoplan and Phase 3 MycarinG study for rozanolixizumab and its open-label extensions^1,2</li> <li><b>Underrecognized perspectives of http://www.streetinsider.com/PRNewswire/UCB+data+presented+at+2026+AANEM+Annual+Meeting+and+MGFA+Scientific+Session+underscore+leadership+in+advancing+targeted+treatments+for+gMG/27117696.html Tue, 29 Sep 2026 08:00:00 -0400 UCBJY